WILMINGTON, DE - Enovis (NYSE: ENOV), a prominent medical technology company with a market capitalization of $2.54 billion, has announced the appointment of Davide Visentin as the new President of Enovis International Surgical, starting March 1, 2025. Visentin, an experienced MedTech executive, brings over two decades of healthcare industry expertise to his new role at Enovis.
Before joining Enovis, Visentin played a significant role as Vice President and General Manager at BD's Integrated Diagnostic Solutions Business Unit, where he led a team of over 700 employees and expanded the company's market share. His prior positions include Vice President and General Manager of Europe for Stryker (NYSE:SYK)'s Joint Replacement and Robotic Division and Vice President, EMEA, for Johnson & Johnson Depuy Synthes.
Visentin's appointment follows the tenure of Dr. Benjamin Reinmann, who has been credited with establishing Enovis's International Surgical Business as a world-class entity and overseeing the integration of legacy companies Mathys and LimaCorporate. Louie Vogt, Group President of Enovis's Reconstructive Business Group, expressed gratitude to Dr. Reinmann for his contributions to the company's growth and success.
Vogt also expressed enthusiasm about Visentin's leadership potential, highlighting his successful business growth track record, passion for orthopedics, and the necessary experience to elevate the company's operations. According to Vogt, Enovis is poised to continue gaining market share and driving growth through innovation, with the overarching goal of enhancing patient outcomes.
Visentin, a University of Milan Computer Science graduate, will be based in Villanova, Italy, and Bettlach, Switzerland, as he takes on his new responsibilities.
Enovis (NYSE: ENOV) is recognized for its commitment to developing clinically differentiated solutions that improve patient outcomes and restore motion for life. Partnering with leading health experts, the company seeks to advance care through smarter, personalized, and more effective treatments, while also enhancing operational efficiency for surgeons and clinicians globally. InvestingPro analysis shows the company maintains a strong financial health score, with analysts projecting profitability this year. For detailed insights and additional ProTips about Enovis's financial outlook, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
The information in this article is based on a press release statement.
In other recent news, Enovis reported a significant year-over-year revenue increase of 21%, reaching $505 million in its third quarter 2024 earnings call. The company also saw its adjusted EBITDA margins improve by 220 basis points to 17.9%. Despite market disruptions, the company's leadership remains confident about future growth, driven by new product launches and integration synergies. Enovis has narrowed its Q4 revenue guidance and raised its adjusted earnings per share forecast, indicating strong performance expectations. The company is also optimistic about robust growth into 2025. The Recon segment, which now constitutes over 50% of the company's revenue, grew by 57%. Enovis is also focusing on integrating Lima, which is expected to have a negative revenue impact of $20 million to $30 million. These are the recent developments in the company's performance and strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.